1. Home
  2. PHAR vs ETJ Comparison

PHAR vs ETJ Comparison

Compare PHAR & ETJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$16.31

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest

ETJ

Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest

HOLD

Current Price

$8.76

Market Cap

592.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAR
ETJ
Founded
1988
2007
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
592.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PHAR
ETJ
Price
$16.31
$8.76
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$38.00
N/A
AVG Volume (30 Days)
22.5K
175.6K
Earning Date
11-06-2025
01-01-0001
Dividend Yield
N/A
8.30%
EPS Growth
N/A
N/A
EPS
0.00
N/A
Revenue
$362,274,000.00
N/A
Revenue This Year
$24.80
N/A
Revenue Next Year
$6.84
N/A
P/E Ratio
$2,946.57
N/A
Revenue Growth
26.78
N/A
52 Week Low
$7.50
$7.20
52 Week High
$18.12
$8.47

Technical Indicators

Market Signals
Indicator
PHAR
ETJ
Relative Strength Index (RSI) 51.06 49.47
Support Level $16.23 $8.61
Resistance Level $17.00 $8.84
Average True Range (ATR) 0.75 0.10
MACD -0.16 -0.01
Stochastic Oscillator 36.44 30.05

Price Performance

Historical Comparison
PHAR
ETJ

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About ETJ Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest

Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.

Share on Social Networks: